Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2030
Roots Analysis is pleased to announce the publication of its recent study, titled, “Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030.”
The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapies over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:
A detailed assessment of the current market landscape of drug developers engaged in the development of next generation immune checkpoint modulators. A detailed analysis of more than 590 completed, ongoing and planned clinical studies of next generation immune checkpoint inhibitors and stimulators. Detailed profiles of developers of next generation immune checkpoint modulators (shortlisted on the basis of the number of pipeline products). An in-depth analysis of more than 490 grants that have been awarded to research institutes engaged in next generation immune checkpoint therapy-related projects. An analysis of the partnerships that have been established in this domain, in the recent past. A competitiveness analysis of biological targets, featuring insightful pictorial summaries and representations. An analysis of the initiatives of big biopharma players engaged in this domain.A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
Next Generation Immune Checkpoint Inhibitors and Stimulators Market Size by 2030
Cancer is known to be one of the leading causes of death worldwide, accounting for 0.6 million deaths in 2019, in the US alone. The World Health Organization has estimated the number of new cancer cases to rise by 70% over the next 20 years, across the globe. Conventional treatment options, such as chemotherapy, surgery and radiation therapy, are still considered as the current standard of care. However, their efficacy is severely limited, especially when it comes to treating late-stage cancers. Moreover, the non-specific and highly toxic nature of chemotherapy and radiation therapy, are known to have a significant adverse impact on patients’ quality of life. There are several targeted anti-cancer therapies that are available in the market and many are presently under development. Of these, immune checkpoint therapies have shown a lot of promise as viable and potent treatment options, capable of preventing tumor cells from evading immune surveillance. In 2011, Bristol-Myers Squibb’s Yervoy® (ipilimumab), an anti-CTLA-4 monoclonal antibody, became the first FDA approved immune checkpoint inhibitor which was designed for the treatment of metastatic melanoma. Yervoy®, along with other first generation immune checkpoint inhibitors (targeting PD-1/PD-L1 and CTLA-4), soon demonstrated the ability to substantially prolong the lives of patients suffering from advanced stage tumors. However, despite the success of PD 1 / PD-L1 inhibitor drugs, there was a notable amount of resistance to treatment reported in certain groups of patients, which compromised the therapeutic potential of this relatively novel class of therapeutics.
Over the years, significant strides have been made in immune checkpoint modulation research, revealing several inhibitory (LAG-3, TIM-3, TIGIT, VISTA and B7-H3) and stimulatory receptors (OX40, ICOS, GITR, 4-1BB and CD40), which are now being exploited for development of next generation immune checkpoint-based therapies. Moreover, clinical studies of combinatorial immune checkpoint blockade / co-stimulation, involving the newly identified checkpoints and known immune checkpoint inhibitor therapies, have demonstrated the potential to further augment therapeutic benefits. It is worth highlighting that these molecules have also shown to be capable of regulating immune tolerance and preventing / treating autoimmune disorders. Therefore, backed by promising clinical results and expanding applicability of therapies being investigated in late stages of development, the immune checkpoint inhibitors and stimulators market is poised to witness substantial growth in the foreseen future.
Target Disease Indication
Breast Cancer Chronic Lymphocytic Leukemia Colorectal Cancer Head and Neck Cancer Lung Cancer Lupus Nephritis Melanoma Multiple Myeloma Primary Sjögren's Syndrome OthersTarget Immune Checkpoint
B7-H3 CD38 CD40 CD47 OthersMechanism of Action
Inhibitory StimulatoryTherapeutic Modality
Monoclonal Antibody Small MoleculeType of Therapy
Monotherapy Combination TherapyRoute of Administration
Intravenous Subcutaneous OthersKey Geographical Region
North America Europe Asia-Pacific and the Rest of the WorldKey companies covered in the report
Bristol Myers Squibb GlaxoSmithKline Incyte Novartis Trillium TherapeuticsGet Customized Reports:
https://www.rootsanalysis.com/reports/303/request-customization.html
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Gaurav.Chaudhary@rootsanalysis.com